IMMUNOMEDICS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2017 12 months to Jun 30, 2018	FY2016 12 months to Jun 30, 2017	FY2015 12 months to Jun 30, 2016	FY2014 12 months to Jun 30, 2015
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities
Warrant related expense
Depreciation and amortization
Loss on disposal of property and equipment
Interest on non-recourse debt
Loss on induced exchanges of debt
Deferred revenue, net of amortization
Amortization of deferred revenue
Amortization of bond premiums
Amortization of debt issuance costs
Amortization of deferred rent
Loss (gain) on sale of marketable securities
Non-cash lease expense
Loss on sale of marketable securities
Decrease in allowance for doubtful accounts
Non-cash expense related to stock-based compensation
Non-cash decrease in value of life insurance policy
Gain on insurance claim for equipment failure
Non-cash financing expenses
Changes in operating assets and liabilities
Accounts receivable, net
Inventories - net of reserve
Inventories, net
Other receivables
Other current assets
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Other liabilities
Deferred revenue
Net cash used in operating activities
Net cash used in operating activities

Cash flows from investing activities:
Purchases of marketable securities
Proceeds from sales/maturities of marketable securities
Purchases of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Exercise of stock options, net
Exercise of warrants
Sale of preferred stock, net of related expenses
Proceeds from public offering of common stock
Proceeds from issuance of convertible senior notes
Payment of debt issuance costs
Proceeds from the issuance of non-recourse debt
Debt conversion fees
Tax withholding payments for stock-based compensation
Net cash provided by financing activities
Effect of changes in exchange rates on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents

Effect of changes in exchange rates on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents, and restricted cash beginning of period
Cash, cash equivalents, and restricted cash end of period
Supplemental disclosure of cash flow information:
Interest paid
Income taxes paid
Schedule of non-cash investing and financing activities:
Issuance of common shares for debt conversion
Accrued capital expenditures
Non-cash component of warrant exercise
Shares received in cashless exercise
Cash and cash equivalents
Restricted cash in other current assets

Comments